By Scientia Professor Gregory John Dore

Journal articles

Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2018, 'Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia', Journal of Viral Hepatitis, 25, pp. 640 - 648, http://dx.doi.org/10.1111/jvh.12852

Lamoury FMJ; Bajis S; Hajarizadeh B; Marshall AD; Martinello M; Ivanova E; Catlett B; Mowat Y; Marks P; Amin J; Smith J; Ezard N; Cock V; Hayllar J; Persing DH; Kleman M; Cunningham P; Dore GJ; Applegate TL; Grebely J, 2018, 'Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay', Journal of Infectious Diseases, 217, pp. 1889 - 1896, http://dx.doi.org/10.1093/infdis/jiy114

Alavi M; Grebely J; Hajarizadeh B; Amin J; Larney S; Law MG; George J; Degenhardt L; Dore GJ, 2018, 'Mortality trends among people with hepatitis B and C: A population-based linkage study, 1993-2012', BMC Infectious Diseases, 18, http://dx.doi.org/10.1186/s12879-018-3110-0

Alavi M; Law MG; Dore GJ, 2018, 'Reply to: “‘Who killed JR’: Chronic hepatitis C or alcohol use disorders?”', Journal of Hepatology, 68, pp. 1099 - 1100, http://dx.doi.org/10.1016/j.jhep.2017.12.021

Dore GJ, 2018, 'Striving for hepatitis C virus elimination or control?', The Lancet Gastroenterology and Hepatology, 3, pp. 295 - 297, http://dx.doi.org/10.1016/S2468-1253(18)30080-3

Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio H; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ, 2018, 'Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study', Journal of Viral Hepatitis, 25, pp. 473 - 481, http://dx.doi.org/10.1111/jvh.12837

Cunningham EB; Hajarizadeh B; Amin J; Bretana N; Dore GJ; Degenhardt L; Larney S; Luciani F; Lloyd AR; Grebely J; Dolan K, 2018, 'Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study', International Journal of Drug Policy, 54, pp. 18 - 25, http://dx.doi.org/10.1016/j.drugpo.2017.12.013

Conway B; Dore GJ; Altice F; Litwin A; Grebely J; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng C; Gendrano I; Huang H; Chen E; Nguyen B; Wahl J; Barr E; Robertson M; Platt H, 2018, 'A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT)', Journal of the Canadian Association of Gastroenterology, 1, pp. 299 - 300, http://dx.doi.org/10.1093/jcag/gwy008.173

Marshall AD; Treloar C; Dore GJ; Grebely J, 2018, 'A239 QUALITATIVE EVALUATION OF THE DECISIONS AND EXPERIENCES OF PEOPLE WHO INJECT DRUGS WHO RECEIVED A LIVER DISEASE ASSESSMENT AS PART OF A LIVER HEALTH PROMOTION CAMPAIGN: THE LIVERLIFE STUDY', Journal of the Canadian Association of Gastroenterology, 1, pp. 419 - 419, http://dx.doi.org/10.1093/jcag/gwy008.240

Waziry R; Gomaa A; Waked I; Dore GJ, 2018, 'Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era', Arab Journal of Gastroenterology, 19, pp. 26 - 32, http://dx.doi.org/10.1016/j.ajg.2018.02.004

Waziry R; Amin J; Law M; Dore GJ, 2018, 'Reply to: “Direct antiviral agents and risk of HCC: Waiting for Godot”', Journal of Hepatology, 68, pp. 616 - 617, http://dx.doi.org/10.1016/j.jhep.2017.10.002

Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ, 2018, 'Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial', The Lancet Gastroenterology and Hepatology, 3, pp. 153 - 161, http://dx.doi.org/10.1016/S2468-1253(17)30404-1

Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ, 2018, 'The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study', Journal of Hepatology, 68, pp. 393 - 401, http://dx.doi.org/10.1016/j.jhep.2017.10.019

Martinello M; Hajarizadeh B; Dore GJ, 2018, 'Observations on the launch of new drugs for hepatitis C', Australian Prescriber, 41, pp. 4 - 5, http://dx.doi.org/10.18773/austprescr.2018.005

Marshall AD; Cunningham EB; Nielsen S; Aghemo A; Alho H; Backmund M; Bruggmann P; Dalgard O; Seguin-Devaux C; Flisiak R; Foster GR; Gheorghe L; Goldberg D; Goulis I; Hickman M; Hoffmann P; Jancorienė L; Jarcuska P; Kåberg M; Kostrikis LG; Makara M; Maimets M; Marinho RT; Matičič M; Norris S; Ólafsson S; Øvrehus A; Pawlotsky JM; Pocock J; Robaeys G; Roncero C; Simonova M; Sperl J; Tait M; Tolmane I; Tomaselli S; van der Valk M; Vince A; Dore GJ; Lazarus JV; Grebely J, 2018, 'Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe', The Lancet Gastroenterology and Hepatology, 3, pp. 125 - 133, http://dx.doi.org/10.1016/S2468-1253(17)30284-4

Grebely J; Feld JJ; Wyles D; Sulkowski M; Ni L; Llewellyn J; Mir HM; Sajed N; Stamm LM; Hyland RH; McNally J; Brainard DM; Jacobson I; Zeuzem S; Bourlière M; Foster G; Afdhal N; Dore GJ, 2018, 'Sofosbuvir-based direct-acting antiviral therapies for HCV in people receiving opioid substitution therapy: An analysis of phase 3 studies', Open Forum Infectious Diseases, 5, http://dx.doi.org/10.1093/ofid/ofy001

Zeuzem S; Foster GR; Wang S; Asatryan A; Gane E; Feld JJ; Asselah T; Bourlière M; Ruane PJ; Wedemeyer H; Pol S; Flisiak R; Poordad F; Chuang WL; Stedman CA; Flamm S; Kwo P; Dore GJ; Sepulveda-Arzola G; Roberts SK; Soto-Malave R; Kaita K; Puoti M; Vierling J; Tam E; Vargas HE; Bruck R; Fuster F; Paik SW; Felizarta F; Kort J; Fu B; Liu R; Ng TI; Pilot-Matias T; Lin CW; Trinh R; Mensa FJ, 2018, 'Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection', New England Journal of Medicine, 378, pp. 354 - 369, http://dx.doi.org/10.1056/NEJMoa1702417

Shepherd SJ; McDonald SA; Palmateer NE; Gunson RN; Aitken C; Dore GJ; Goldberg DJ; Applegate TL; Lloyd AR; Hajarizadeh B; Grebely J; Hutchinson SJ, 2018, 'HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype', Journal of Medical Virology, 90, pp. 120 - 130, http://dx.doi.org/10.1002/jmv.24919

Esmaeili A; Mirzazadeh A; Morris MD; Hajarizadeh B; Sacks HS; Maher L; Grebely J; Kim AY; Lauer G; Cox AL; Hellard M; Dietze P; Bruneau J; Shoukry NH; Dore GJ; Lloyd AR; Prins M; Page K, 2018, 'The Effect of Female Sex on Hepatitis C Incidence among People Who Inject Drugs: Results from the International Multicohort InC3 Collaborative', Clinical Infectious Diseases, 66, pp. 20 - 28, http://dx.doi.org/10.1093/cid/cix768

Hezode C; Kwo P; Sperl J; Dore G; Hwang P; Long J; Talwani R; Robertson M; Haber B, 2018, 'Efficacy and safety of Elbasvir/Grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy', Journal of Hepatology, 68, pp. S264 - S265, http://dx.doi.org/10.1016/s0168-8278(18)30742-6

Boettiger DC; Law MG; Dore GJ; Guy R; Callander D; Donovan B; O'Connor CC; Fairley CK; Hellard M; Matthews G; Han A, 2017, 'Hepatitis C testing and re-testing among people attending sexual health services in Australia, and hepatitis C incidence among people with human immunodeficiency virus: Analysis of national sentinel surveillance data', BMC Infectious Diseases, 17, pp. 740, http://dx.doi.org/10.1186/s12879-017-2848-0

Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ, 2017, 'Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression', Journal of Hepatology, 67, pp. 1204 - 1212, http://dx.doi.org/10.1016/j.jhep.2017.07.025

Grebely J; Hajarizadeh B; Dore GJ, 2017, 'Direct-Acting antiviral agents for HCV infection affecting people who inject drugs', Nature Reviews Gastroenterology and Hepatology, 14, pp. 641 - 651, http://dx.doi.org/10.1038/nrgastro.2017.106

Samji H; Yu A; Kuo M; Alavi M; Woods R; Alvarez M; Dore GJ; Tyndall M; Krajden M; Janjua NZ, 2017, 'Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development', Journal of Hepatology, 67, pp. 909 - 917, http://dx.doi.org/10.1016/j.jhep.2017.06.025

Dore GJ; Hatzakis A; Negro F; Waked I, 2017, 'Estimating HCV disease burden—volume 4 (editorial)', Journal of Viral Hepatitis, 24, pp. 4 - 7, http://dx.doi.org/10.1111/jvh.12763

Larney S; Hickman M; Guy R; Grebely J; Dore GJ; Gray RT; Day CA; Kimber J; Degenhardt L, 2017, 'Estimating the number of people who inject drugs in Australia', BMC Public Health, 17, pp. 757, http://dx.doi.org/10.1186/s12889-017-4785-7

Marshall AD; Grebely J; Dore GJ; Treloar C, 2017, '‘I didn't want to let it go too far.’ The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study', International Journal of Drug Policy, 47, pp. 153 - 160, http://dx.doi.org/10.1016/j.drugpo.2017.06.001

Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J, 2017, 'Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study', International Journal of Drug Policy, 47, pp. 230 - 238, http://dx.doi.org/10.1016/j.drugpo.2017.05.040

Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I, 2017, 'Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting', International Journal of Drug Policy, 47, pp. 209 - 215, http://dx.doi.org/10.1016/j.drugpo.2017.05.032

Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ, 2017, 'Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', International Journal of Drug Policy, 47, pp. 177 - 186, http://dx.doi.org/10.1016/j.drugpo.2017.05.020

Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L, 2017, 'Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia', International Journal of Drug Policy, 47, pp. 77 - 85, http://dx.doi.org/10.1016/j.drugpo.2017.05.022

Bajis S; Dore GJ; Hajarizadeh B; Cunningham EB; Maher L; Grebely J, 2017, 'Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review', International Journal of Drug Policy, 47, pp. 34 - 46, http://dx.doi.org/10.1016/j.drugpo.2017.07.002

Cunningham EB; Hajarizadeh B; Bretana NA; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Dolan K; Lloyd AR; Grebely J; Haber P; Rawlinson W; Treloar C; Maher L, 2017, 'Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study', Journal of Viral Hepatitis, 24, pp. 733 - 741, http://dx.doi.org/10.1111/jvh.12701

Grebely J; Bruneau J; Lazarus JV; Dalgard O; Bruggmann P; Treloar C; Hickman M; Hellard M; Roberts T; Crooks L; Midgard H; Larney S; Degenhardt L; Alho H; Byrne J; Dillon JF; Feld JJ; Foster G; Goldberg D; Lloyd AR; Reimer J; Robaeys G; Torrens M; Wright N; Maremmani I; Norton BL; Litwin AH; Dore GJ, 2017, 'Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs', International Journal of Drug Policy, 47, pp. 51 - 60, http://dx.doi.org/10.1016/j.drugpo.2017.05.019

Kwo PY; Poordad F; Asatryan A; Wang S; Wyles DL; Hassanein T; Felizarta F; Sulkowski MS; Gane E; Maliakkal B; Overcash JS; Gordon SC; Muir AJ; Aguilar H; Agarwal K; Dore GJ; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ, 2017, 'Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis', Journal of Hepatology, 67, pp. 263 - 271, http://dx.doi.org/10.1016/j.jhep.2017.03.039

Dore GJ, 2017, 'Commentary on Gountas et al. (2017): Time to focus on empirical evidence for HCV treatment as prevention', Addiction, 112, pp. 1300 - 1301, http://dx.doi.org/10.1111/add.13796

Jacobson IM; Lawitz E; Gane EJ; Willems BE; Ruane PJ; Nahass RG; Borgia SM; Shafran SD; Workowski KA; Pearlman B; Hyland RH; Stamm LM; Svarovskaia E; Dvory-Sobol H; Zhu Y; Subramanian GM; Brainard DM; McHutchison JG; Bräu N; Berg T; Agarwal K; Bhandari BR; Davis M; Feld JJ; Dore GJ; Stedman CAM; Thompson AJ; Asselah T; Roberts SK; Foster GR, 2017, 'Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials', Gastroenterology, 153, pp. 113 - 122, http://dx.doi.org/10.1053/j.gastro.2017.03.047

Grebely J; Lamoury FMJ; Hajarizadeh B; Mowat Y; Marshall AD; Bajis S; Marks P; Amin J; Smith J; Edwards M; Gorton C; Ezard N; Persing D; Kleman M; Cunningham P; Catlett B; Dore GJ; Applegate TL, 2017, 'Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study', The Lancet Gastroenterology and Hepatology, 2, pp. 514 - 520, http://dx.doi.org/10.1016/S2468-1253(17)30075-4

Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M; Conway B; Robaeys G; Swan T; Cloherty G; Marks P; Grebely J; Dore GJ; Applegate TL, 2017, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse', Journal of Clinical Virology, 92, pp. 32 - 38, http://dx.doi.org/10.1016/j.jcv.2017.05.007

Cunningham EB; Hajarizadeh B; Dalgard O; Amin J; Hellard M; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Bruneau J; Midgard H; Bourgeois S; Thurnheer MC; Dore GJ; Grebely J; Shaw I; Siriragavan S; Horschik T; Sharma S; Eevers A; Andreassen J; Melkeraaen I; Widder N; Lesneuck K; Kotsoros B; Hazelwood S; Holland R; Axten D; Von Bibra S; Powis J; Mason K; Ryder S; Jack K; Scheidegger C; Huber C; Ferguson C; Staehelin C; Lacalamita M; Fragomeli V; Sevehon A, 2017, 'Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', BMC Infectious Diseases, 17, pp. 420, http://dx.doi.org/10.1186/s12879-017-2517-3

Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2017, 'HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs', Current HIV/AIDS Reports, 14, pp. 110 - 121, http://dx.doi.org/10.1007/s11904-017-0358-8

Bartlett SR; Wertheim JO; Bull RA; Matthews GV; Lamoury FMJ; Scheffler K; Hellard M; Maher L; Dore GJ; Lloyd AR; Applegate TL; Grebely J, 2017, 'A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies', Journal of Viral Hepatitis, 24, pp. 404 - 411, http://dx.doi.org/10.1111/jvh.12652

Martinello M; Grebely J; Petoumenos K; Gane E; Hellard M; Shaw D; Sasadeusz J; Applegate TL; Dore GJ; Matthews GV, 2017, 'HCV reinfection incidence among individuals treated for recent infection', Journal of Viral Hepatitis, 24, pp. 359 - 370, http://dx.doi.org/10.1111/jvh.12666

Eslam M; McLeod D; Kelaeng KS; Mangia A; Berg T; Thabet K; Irving WL; Dore GJ; Sheridan D; Grønbæk H; Abate ML; Hartmann R; Bugianesi E; Spengler U; Rojas A; Booth DR; Weltman M; Mollison L; Cheng W; Riordan S; Mahajan H; Fischer J; Nattermann J; Douglas MW; Liddle C; Powell E; Romero-Gomez M; George J; Metwally M; White R; Gallego-Duran R; Leung R; Mahajan N; Bassendine M; Rahme A; Rosso C; Mezzabotta L; Malik B; Matthews G; Asimakopoulos A; Applegate T; Grebely J; Fragomeli V; Jonsson JR; Santoro R, 2017, 'IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis', Nature Genetics, 49, pp. 795 - 800, http://dx.doi.org/10.1038/ng.3836

Zeuzem S; Mizokami M; Pianko S; Mangia A; Han KH; Martin R; Svarovskaia E; Dvory-Sobol H; Doehle B; Hedskog C; Yun C; Brainard DM; Knox S; McHutchison JG; Miller MD; Mo H; Chuang WL; Jacobson I; Dore GJ; Sulkowski M, 2017, 'NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome', Journal of Hepatology, 66, pp. 910 - 918, http://dx.doi.org/10.1016/j.jhep.2017.01.007

Morris MD; Shiboski S; Bruneau J; Hahn JA; Hellard M; Prins M; Cox AL; Dore G; Grebely J; Kim AY; Lauer GM; Lloyd A; Rice T; Shoukry N; Maher L; Page K, 2017, 'Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: The InC3 collaboration', Clinical Infectious Diseases, 64, pp. 860 - 869, http://dx.doi.org/10.1093/cid/ciw869

Haber B; Gane E; Dore GJ; Grebely J; Altice F; Litwin AH; Dalgard O; Shibolet O; Luetkemeyer A; Nahass R; Peng C-Y; Conway B; Iser DM; Huang H-C; Gendrano IN; Kelly M; Hwang P; Robertson M; Wahl J; Barr E; Platt HL, 2017, 'HEPATITIS C VIRUS (HCV) REINFECTION AND INJECTION RISK BEHAVIOR FOLLOWING ELBASVIR/GRAZOPREVIR (EBR/GZR) TREATMENT IN PATIENTS ON OPIOID AGONIST THERAPY (OAT): CO-STAR THREE-YEAR FOLLOW-UP STUDY', GASTROENTEROLOGY, 152, pp. S1058 - S1059, http://dx.doi.org/10.1016/S0016-5085(17)33575-8

Rodrigo C; Walker MR; Leung P; Eltahla AA; Grebely J; Dore GJ; Applegate T; Page K; Dwivedi S; Bruneau J; Morris MD; Cox AL; Osburn W; Kim AY; Schinkel J; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Luciani F; Lloyd AR; Bull RA, 2017, 'Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection', Infection, Genetics and Evolution, 49, pp. 88 - 96, http://dx.doi.org/10.1016/j.meegid.2017.01.006

Grebely J; Dore GJ, 2017, 'Treatment of HCV in persons who inject drugs: Treatment as prevention', Clinical Liver Disease, 9, pp. 77 - 80, http://dx.doi.org/10.1002/cld.626

Ghinea N; Lipworth W; Day R; Hill A; Dore GJ; Danta M, 2017, 'Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries', The Lancet, 389, pp. 1268 - 1272, http://dx.doi.org/10.1016/S0140-6736(16)32051-7

Back to profile page